Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lactobacillus rhamnosus JL-1
- Development stage
- Preclinical
- Lead developer
- Northeast Agricultural University
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus rhamnosus JL-1 is a probiotic bacterial strain isolated from the feces of healthy infants, currently under investigation as a live biotherapeutic product (LBP). Developed by researchers at the Northeast Agricultural University in China, the strain is being studied for its potential to treat and prevent diet-induced obesity and related metabolic complications, such as hyperlipidemia and hepatic steatosis. Its mechanism of action involves the activation of the AMPK signaling pathway and the regulation of key lipid metabolism factors, including PPAR-γ, LXR-α, and SREBP-1C. Preclinical studies in mouse models have demonstrated that JL-1 can effectively reduce body weight, serum total cholesterol, and triglycerides while promoting the production of beneficial short-chain fatty acids in the gastrointestinal tract.
- Other names
- Lactobacillus rhamnosus JL1鼠李糖乳酪杆菌JL-1
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)AMPK (Adenosine monophosphate–activated protein kinase)NR1H3 (Liver X receptor beta)SREBP-1 / SREBF1 (SREBP-1)
Beyond the preview
Go deeper on lactobacillus rhamnosus JL-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lactobacillus rhamnosus JL-1.